Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice.

@article{Dharnidharka2018CenterPD,
  title={Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice.},
  author={Vikas R Dharnidharka and Abhijit S. Naik and David A Axelrod and Mark A. Schnitzler and Zidong Zhang and Sunjae Bae and Dorry L Segev and Daniel C. Brennan and Tarek Alhamad and Rosemary Ouseph and Ngan N. Lam and Mustafa Darwish Nazzal and Henry B. Randall and Bertram L. Kasiske and Mara A McAdams-DeMarco and Krista L Lentine},
  journal={Transplant international : official journal of the European Society for Organ Transplantation},
  year={2018},
  volume={31 2},
  pages={
          198-211
        }
}
To assess factors that influence the choice of induction regimen in contemporary kidney transplantation, we examined center-identified, national transplant registry data for 166 776 US recipients (2005-2014). Bilevel hierarchical models were constructed, wherein use of each regimen was compared pairwise with use of interleukin-2 receptor blocking antibodies (IL2rAb). Overall, 82% of patients received induction, including thymoglobulin (TMG, 46%), IL2rAb (22%), alemtuzumab (ALEM, 13%), and other… CONTINUE READING